Page last updated: 2024-11-09

isoferulic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isoferulic acid: isomer of ferulic acid; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID736186
CHEMBL ID233295
CHEBI ID27794
SCHEMBL ID249041
SCHEMBL ID249042
MeSH IDM0051805

Synonyms (83)

Synonym
LS-13768
3-hydroxy-4-methoxycinnamic acid
hesperetic acid
nsc-51987
nsc51987
2-propenoic acid, 3-(3-hydroxy-4-methoxyphenyl)-
cinnamic acid, 3-hydroxy-4-methoxy-
nsc 51987
3-(3-hydroxy-4-methoxyphenyl)-2-propenoic acid
einecs 208-676-0
brn 2212760
isoferulic acid
537-73-5
3-hydroxy-4-methoxycinnamic acid, predominantly trans, 97%
smr001215828
MLS000563054
(2e)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid
4fe ,
bdbm50241245
(e)-3-(3-hydroxy-4-methoxyphenyl)acrylic acid
AKOS000141174
DB07109
CHEMBL233295 ,
chebi:27794 ,
(e)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid
BMSE000618
3-hydroxy-4-methoxycinnamic acid, predominantly trans
3-hydroxy-4-methoxy-cinnamic acid
3-[3-hydroxy-4-(methoxy-d3)phenyl]-2-propenoic acid
H0524
3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid
NCGC00247490-01
EN300-50983
3-(3-hydroxy-4-methoxyphenyl)acrylic acid
(e)-3'-hydroxy-4'-methoxycinnamic acid
25522-33-2
einecs 247-071-6
HMS2268G06
4-10-00-01777 (beilstein handbook reference)
xsq2k2g7mc ,
unii-xsq2k2g7mc
S3764
AM20040660
4-o-methylcaffeic acid
isoferulic acid (constituent of black cohosh) [dsc]
(e)-3-(3-hydroxy-4-methoxy-phenyl)-acrylic acid
(2e)-3-(3-hydroxy-4-methoxyphenyl)acrylic acid
SCHEMBL249041
SCHEMBL249042
MS-11465
STR05122
Q-100609
3-hydroxy-4-methoxycinnamic-acid
gtpl7980
(2e)-3-(3-hydroxy-4-methoxyphenyl)-2-propenoic acid #
Z2693271860
isoferulate
hesperetate
mfcd00004391
trans-isoferulic acid, analytical standard
hesperetinic acid
isoferulasaure
3-hydroxy-4-methoxy-cinnamate
3-(3-hydroxy-4-methoxyphenyl)-2-propenoate
3-hydroxy-4-methoxycinnamate
CS-W020120
HY-N0761
isoferulic acid ,(s)
Q27096447
trans-isoferulic acid
(e)-4-hydroxy-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one
(e)-3-(3-hydroxy-4-methoxyphenyl)acrylicacid
STL186177
BBL036268
CCG-266533
trans-3-hydroxy-4-methoxycinnamic acid
NCGC00247490-02
3-hydroxy-4-methoxycinnamic acid (isoferulic acid)
EN300-331979
AC-34927
DTXSID901314847
dtxcid90908460
isoferulic acid (constituent of black cohosh)

Research Excerpts

Overview

Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia. It is used frequently in Japanese traditional medicine as an anti-inflammatory drug.

ExcerptReferenceRelevance
"Isoferulic acid is a unique biomarker as it is not a dietary component, however, dihydroferulic acid may well derive from other flavonoids with a structurally related B-ring."( Novel biomarkers of the metabolism of caffeic acid derivatives in vivo.
Hahn, U; Kuhnle, G; Rechner, AR; Rice-Evans, CA; Spencer, JP, 2001
)
1.03
"Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. "( Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
Kogure, T; Mantani, N; Ochiai, H; Sakai, S; Shibahara, N; Terasawa, K, 2001
)
2.09

Pharmacokinetics

ExcerptReferenceRelevance
" The validated method was successfully applied to the pharmacokinetic study of isoferulic acid in rat plasma after oral administration of isoferulic acid and Rhizoma Cimicifugae extract."( Determination and pharmacokinetics of isoferulic acid in rat plasma by high-performance liquid chromatography after oral administration of isoferulic acid and Rhizoma Cimicifugae extract.
Bi, K; Chen, X; Qi, D; Si, D; Sun, X, 2008
)
0.84

Bioavailability

ExcerptReferenceRelevance
"The purpose of this study was to investigate biomarkers of the bioavailability and metabolism of hydroxycinnamate derivatives through the determination of the pharmacokinetics of their urinary elimination and identification of the metabolites excreted."( Novel biomarkers of the metabolism of caffeic acid derivatives in vivo.
Hahn, U; Kuhnle, G; Rechner, AR; Rice-Evans, CA; Spencer, JP, 2001
)
0.31
" However, data on the bioavailability of CGA from green coffee in humans are inexistent."( Chlorogenic acids from green coffee extract are highly bioavailable in humans.
Donangelo, CM; Farah, A; Lafay, S; Monteiro, M, 2008
)
0.35
" These data suggest that sulfates are the predominant hydroxycinnamic acid conjugates in humans, and that SULT mediated sulfation is a major factor determining the bioavailability of hydroxycinnamic acids in vivo."( In vitro and in vivo conjugation of dietary hydroxycinnamic acids by UDP-glucuronosyltransferases and sulfotransferases in humans.
Barron, D; Crozier, A; Glatt, HR; Meinl, W; Stalmach, A; Steiling, H; Williamson, G; Wong, CC, 2010
)
0.36
" They are becoming of interest for their health-promoting effects, but bioavailability in humans is not well understood."( Nondairy creamer, but not milk, delays the appearance of coffee phenolic acid equivalents in human plasma.
Barron, D; Cavin, C; Dionisi, F; Enslen, M; Fraering, AL; Guy, P; Kochhar, S; Longet, K; Marmet, C; Moulin, J; Renouf, M; Rezzi, S; Steiling, H; Williamson, G, 2010
)
0.36
" Nevertheless, their predictive value for bioavailability can be questioned."( A Critical Evaluation of In Vitro Hesperidin 2S Bioavailability in a Model Combining Luminal (Microbial) Digestion and Caco-2 Cell Absorption in Comparison to a Randomized Controlled Human Trial.
Grootaert, C; Jacobs, G; Noten, B; Pitart, J; Possemiers, S; Salden, B; Smagghe, G; Van Camp, J; Van Rymenant, E; Voorspoels, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
biomarkerA substance used as an indicator of a biological state.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ferulic acids
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency25.91850.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
Guanine nucleotide-binding protein GHomo sapiens (human)Potency3.98111.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)115.20000.03403.987110.0000AID590195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
response to reactive oxygen speciesHyaluronidase-1Homo sapiens (human)
carbohydrate metabolic processHyaluronidase-1Homo sapiens (human)
glycosaminoglycan catabolic processHyaluronidase-1Homo sapiens (human)
inflammatory responseHyaluronidase-1Homo sapiens (human)
response to virusHyaluronidase-1Homo sapiens (human)
positive regulation of epithelial cell migrationHyaluronidase-1Homo sapiens (human)
chondroitin sulfate catabolic processHyaluronidase-1Homo sapiens (human)
hyaluronan metabolic processHyaluronidase-1Homo sapiens (human)
hyaluronan biosynthetic processHyaluronidase-1Homo sapiens (human)
hyaluronan catabolic processHyaluronidase-1Homo sapiens (human)
positive regulation of cell growthHyaluronidase-1Homo sapiens (human)
negative regulation of cell growthHyaluronidase-1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHyaluronidase-1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusHyaluronidase-1Homo sapiens (human)
positive regulation of angiogenesisHyaluronidase-1Homo sapiens (human)
positive regulation of cell adhesionHyaluronidase-1Homo sapiens (human)
positive regulation of growthHyaluronidase-1Homo sapiens (human)
response to antibioticHyaluronidase-1Homo sapiens (human)
positive regulation of epithelial cell proliferationHyaluronidase-1Homo sapiens (human)
cartilage developmentHyaluronidase-1Homo sapiens (human)
embryonic skeletal joint morphogenesisHyaluronidase-1Homo sapiens (human)
cellular response to interleukin-1Hyaluronidase-1Homo sapiens (human)
cellular response to tumor necrosis factorHyaluronidase-1Homo sapiens (human)
cellular response to pHHyaluronidase-1Homo sapiens (human)
cellular response to UV-BHyaluronidase-1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleHyaluronidase-1Homo sapiens (human)
positive regulation of hyaluranon cable assemblyHyaluronidase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
virus receptor activityHyaluronidase-1Homo sapiens (human)
hyalurononglucosaminidase activityHyaluronidase-1Homo sapiens (human)
hyaluronan synthase activityHyaluronidase-1Homo sapiens (human)
chondroitin hydrolase activityHyaluronidase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
extracellular spaceHyaluronidase-1Homo sapiens (human)
cytoplasmHyaluronidase-1Homo sapiens (human)
lysosomeHyaluronidase-1Homo sapiens (human)
cytoplasmic vesicleHyaluronidase-1Homo sapiens (human)
hyaluranon cableHyaluronidase-1Homo sapiens (human)
lysosomal lumenHyaluronidase-1Homo sapiens (human)
extracellular exosomeHyaluronidase-1Homo sapiens (human)
cytoplasmic vesicleHyaluronidase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID334276Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay2002Journal of natural products, May, Volume: 65, Issue:5
Constituents of Chinese propolis and their antiproliferative activities.
AID1248399Inhibition of alpha-amylase (unknown origin) relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
AID590195Inhibition of mushroom tyrosinase after 25 mins by spectrophotometry2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and structure-activity relationships of phenylpropanoid amides of serotonin on tyrosinase inhibition.
AID642414Estrogenic activity at ERalpha in human MVLN cells at 100 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID423636Cytotoxicity against human HeLa cells by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Cytotoxic constituents of chinese propolis.
AID477408Inhibition of hyaluronidase2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Phenolic constituents of the aerial parts of Cimicifuga simplex and Cimicifuga japonica.
AID638451Cytotoxicity against mouse RAW264.7 cells by CCK assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Inhibitory constituents of Nardostachys chinensis on nitric oxide production in RAW 264.7 macrophages.
AID334278Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2002Journal of natural products, May, Volume: 65, Issue:5
Constituents of Chinese propolis and their antiproliferative activities.
AID1456006Antioxidant activity assessed as DPPH radical scavenging activity measured after 30 mins2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease.
AID638450Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Inhibitory constituents of Nardostachys chinensis on nitric oxide production in RAW 264.7 macrophages.
AID1631834Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms after 72 hrs by resazurin-based assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID334279Antiproliferative activity against mouse 26-L5 cells after 72 hrs by MTT assay2002Journal of natural products, May, Volume: 65, Issue:5
Constituents of Chinese propolis and their antiproliferative activities.
AID750756Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID750755Inhibition of Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus laevis oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents at 1 mM after 30 secs by voltage clamp technique2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID294172Inhibition of diphenolase activity of mushroom tyrosinase at 0.035 mM2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Identification of tyrosinase inhibitors from Marrubium velutinum and Marrubium cylleneum.
AID590194Antioxidant activity assessed as DPPH radical scavenging activity by spectrophotometry2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and structure-activity relationships of phenylpropanoid amides of serotonin on tyrosinase inhibition.
AID334275Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay2002Journal of natural products, May, Volume: 65, Issue:5
Constituents of Chinese propolis and their antiproliferative activities.
AID642415Estrogenic activity at ERalpha in human MVLN cells at 20 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID334277Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2002Journal of natural products, May, Volume: 65, Issue:5
Constituents of Chinese propolis and their antiproliferative activities.
AID750752Dissociation constant, pKa of the compound2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID1346806Rat phosphomevalonate kinase (Lanosterol biosynthesis pathway)1979The Biochemical journal, Jul-01, Volume: 181, Issue:1
Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.08)18.7374
1990's8 (12.31)18.2507
2000's20 (30.77)29.6817
2010's30 (46.15)24.3611
2020's5 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.10 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.47%)5.53%
Reviews1 (1.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]